A phase I study of hepatic arterial infusion using difluoromethylornithine.
Ten patients with metastatic disease to the liver were treated with difluoromethylornithine (DFMO) administered by continuous hepatic arterial infusion. Two of nine evaluable patients had an objective partial response. Stable disease was recorded in three patients. Ototoxicity was encountered in all patients who received a daily dose of DFMO equal to or greater than 1.0 g/m2.
Lipton
A
A
Division of Oncology, Milton S. Hershey Medical Center, Pennsylvania State University, Hershey 17033.
Harvey
H A
HA
Glenn
J
J
Weidner
W A
WA
Strauss
M
M
Miller
S E
SE
Taylor
J B
JB
White-Hershey
D
D
Barlow
J L
JL
D000328:Adult; D000368:Aged; D004341:Drug Evaluation; D000518:Eflornithine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006312:Hearing Loss, Bilateral / Q000139:chemically induced; D006499:Hepatic Artery; D006801:Humans; D007261:Infusions, Intra-Arterial; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary*; D008875:Middle Aged
D000518:Eflornithine